Levo Therapeutics has started patient enrolment in its Phase III CARE-PWS clinical study to evaluate the effectiveness of intranasal carbetocin (LV-101) for the treatment of Prader-Willi syndrome (PWS).

PWS is a complex, multisystem neurodevelopmental disorder that affects nearly one in 16,000 births.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The CARE-PWS trial follows the successful completion of a Phase II study of intranasal carbetocin and is currently enrolling subjects at the University of Florida and Vanderbilt University in the US.

Levo aims to enrol 175 subjects for the multi-centre, randomised, double-blind trial.

“Hyperphagia, obsessive and compulsive symptoms, and anxiety are debilitating symptoms of the syndrome.”

Subjects will receive intranasal carbetocin after completing the eight-week placebo-controlled phase.

At week eight, subjects who received placebo will be randomised to receive one of the two doses of intranasal carbetocin three times a day before meals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial intends to assess the effectiveness of LV-101 using both caregiver-reported and clinician-reported measures of hyperphagia (extreme hunger), obsessive and compulsive behaviors, as well as anxiety.

It also aims to measure safety and tolerability using adverse events, laboratory tests, and physical exams.

The trial will feature a long-term follow-up period of 56 weeks.

University of Florida Gainesville MD Jennifer Miller said: “Hyperphagia, obsessive and compulsive symptoms, and anxiety are debilitating symptoms of the syndrome.”

Levo’s intranasal carbetocin is an analogue of neuroendocrine hormone oxytocin and is developed to have an improved receptor binding profile compared to oxytocin.